Gold nanorod-assisted theranostic solution for nonvisible residual disease in bladder cancer

• 成果类型: Article
• 署名作者: Armanetti, Paolo; Locatelli, Irene; Venegoni, Chiara; Alchera, Elisa; Campanella, Beatrice; Pederzoli, Filippo; Maturi, Mirko; Locatelli, Erica; Tortorella, Silvia; Curnis, Flavio; Corti, Angelo; Luciano, Roberta; Onor, Massimo; Salonia, Andrea; Montorsi, Francesco; Moschini, Marco; Popov, Viktor; Jose, Jithin; Franchini, Mauro Comes; Ooi, Ean Hin; Menichetti, Luca; Alfano, Massimo
• 署名单位: Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; University of Bologna; Fujifilm Corporation; Monash University; Monash University Malaysia
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-11342
• DOI: 10.1073/pnas.2411583121
• 发表日期: 2024-09-10
• 关键词: photodynamic diagnosis; expression; carcinoma; therapy; cystoscopy; burden; care

摘要

Residual nonvisible bladder cancer after proper treatment caused by technological and therapeutic limitations is responsible for tumor relapse and progression. This study aimed to demonstrate the feasibility of a solution for simultaneous detection and treatment of bladder cancer lesions smaller than one millimeter. The alpha 5f31 integrin was identified as a specific marker in 81% of human high- grade nonmuscle invasive bladder cancers and used as a target for the delivery of targeted gold nanorods (GNRs). In a preclinical model of orthotopic bladder cancer expressing the alpha 5f31 integrin, the photoacoustic imaging of targeted GNRs visualized lesions smaller than one millimeter, and their irradiation with continuous laser was used to induce GNR- assisted hyperthermia. Necrosis of the tumor mass, improved survival, and computational modeling were applied to demonstrate the efficacy and safety of this solution. Our study highlights the potential of the GNR- assisted theranostic strategy as a complementary solution in clinical practice to reduce the risk of nonvisible residual bladder cancer after current treatment. Further validation through clinical studies will support the findings of the present study.